文献速递其他结缔组织病

炎症性肌病中抗四半LIM结构域1(FHL1)自身抗体的研究:澳大利亚单中心队列结果

Autoantibodies against four-and-a-half-LIM domain 1 (FHL1) in inflammatory myopathies: results from an Australian single-centre cohort.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

该研究检测了南澳大利亚267例经组织学确诊的特发性炎症性肌病(IIM)患者、174例系统性硬化症(SSc)患者和100例健康对照者血清中的抗FHL1自身抗体。结果显示IIM患者抗FHL1抗体阳性率为13.8%,高于SSc的7%(P<0.02)和健康对照的2%(P<0.001),且78%的抗FHL1阳性患者未检出肌炎特异性自身抗体。

要点

  • IIM患者抗FHL1抗体阳性率为13.8%,显著高于SSc的7%和健康对照的2%。
  • 抗FHL1阳性IIM患者中78%未检出肌炎特异性自身抗体。
  • 抗FHL1抗体也见于7%的SSc患者,提示其可能并非肌炎特异性。

核心结论

  • 在经组织学确诊的大规模IIM队列中,抗FHL1自身抗体阳性率为13.8%,其中75%的病例未检出肌炎特异性自身抗体。
  • 抗FHL1自身抗体也见于7%的SSc患者,提示该抗体可能并非肌炎特异性。
  • HLA-DR关联的趋势可能提示针对FHL1蛋白存在特异性免疫应答。

研究设计与样本

  • 研究纳入南澳大利亚肌炎数据库(SAMD)中经组织学确诊的IIM患者267例、澳大利亚硬皮病队列研究(ASCS)的SSc患者174例及健康对照100例,采用酶联免疫吸附试验(ELISA)检测抗FHL1自身抗体。

主要发现

  • IIM患者抗FHL1抗体阳性率为13.8%(37/267),高于SSc患者的7%(12/174,P<0.02)和健康对照的2%(2/100,P<0.001)。
  • 抗FHL1阳性IIM患者中最常见的亚型为(原文此处写作32%)和IBM(2/37,32%),原文此处表述有矛盾。
  • 抗FHL1阳性与阴性IIM患者在肌肉或肌肉外表现上无统计学显著差异。
  • 37例抗FHL1阳性患者中29例(78%)未检出肌炎特异性自身抗体(MSA)。
  • 抗FHL1阳性肌肉活检中CD45+细胞浸润频率较低(P=0.04)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine the prevalence and associations of autoantibodies targeting a muscle-specific autoantigen, four-and-a-half-LIM-domain 1 (FHL1), in South Australian patients with histologically-confirmed idiopathic inflammatory myopathies (IIM) and in patients with SSc. MATERIAL AND METHODS: Sera from patients with IIM (n = 267) from the South Australian Myositis Database (SAMD), SSc (n = 174) from the Australian Scleroderma Cohort Study (ASCS) and healthy controls (HC, n = 100) were analysed for anti-FHL1 autoantibodies by Enzyme-Linked ImmunoSorbent Assay (ELISA). RESULTS: Autoantibodies to FHL1 were more frequent in patients with IIM (37/267, 13.8%) compared with SSc (12/174, 7%) (P < 0.02) and HC (2/100, 2%) (P < 0.001). The most common IIM subtypes among FHL1+ IIM patients were (32%) and IBM (2/37, 32%). No statistically significant differences in muscular or extra-muscular manifestations of IIM were found when comparing patients who were anti-FHL1+ with their anti-FHL1- counterparts. In 29/37 (78%) anti-FHL1+ patients, no myositis-specific autoantibodies (MSA) were present. In FHL1+ muscle biopsies, there was less frequent infiltration by CD45+ cells (P = 0.04). There was a trend for HLA alleles DRB1*07 and DRB1*15 to be more frequent in anti-FHL1+ compared with anti-FHL1- patients (9/25 vs 19/113, P = 0.09 and 8/25 vs 15/114, P = 0.09, respectively). CONCLUSIONS: We report a substantial prevalence (13.8%) of anti-FHL1 autoantibodies in a large cohort of patients with histologically confirmed IIM; 75% of these cases did not have a detectable myositis-specific autoantibody. Anti-FHL1 autoantibodies were also detected in a subgroup of patients with SSc (7%), indicating that anti-FHL1 autoantibodies may not be myositis-specific. The trend towards an HLA-DR association might indicate a specific immune response to the FHL1 protein.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Galindo-Feria AS, Horuluoglu B, Day J, et al. Autoantibodies against four-and-a-half-LIM domain 1 (FHL1) in inflammatory myopathies: results from an Australian single-centre cohort. Rheumatology (Oxford). 2022. PMID: 35022656. doi:10.1093/rheumatology/keac003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。